scholarly journals Potential Roles of CD34+ Fibrocytes Masquerading as Orbital Fibroblasts in Thyroid-Associated Ophthalmopathy

2018 ◽  
Vol 104 (2) ◽  
pp. 581-594 ◽  
Author(s):  
Terry J Smith

Abstract Context Orbital tissues in thyroid-associated ophthalmopathy exhibit particular reactivity and undergo characteristic remodeling. Mechanisms underlying these changes have remained largely unexplained. Studies have characterized orbital connective tissues and derivative fibroblasts to gain insights into local manifestations of a systemic autoimmune syndrome. Evidence Acquisition A systematic search of PubMed was undertaken for studies related to thyroid-associated ophthalmopathy (TAO), orbital fibroblasts, and fibrocytes involved in pathogenesis. Evidence Synthesis Orbital tissues display marked cellular heterogeneity. Fibroblast subsets, putatively derived from multiple precursors, inhabit the orbit in TAO. Among them are cells displaying the CD34+CXC chemokine receptor 4+collagen I+ phenotype, identifying them as fibrocytes, derived from the monocyte lineage. Their unique presence in the TAO orbit helps explain the tissue reactivity and characteristic remodeling that occurs in the disease. Their unanticipated expression of several proteins traditionally thought to be thyroid gland specific, including the TSH receptor and thyroglobulin, may underlie orbital involvement in Graves disease. Although no currently available information unambiguously establishes that CD34+ orbital fibroblasts originate from circulating fibrocytes, inferences from animal models of lung disease suggest that they derive from bone marrow. Further studies are necessary to determine whether fibrocyte abundance and activity in the orbit determine the clinical behavior of TAO. Conclusion Evidence supports a role for fibrocytes in the pathogenesis of TAO. Recognition of their presence in the orbit now allows development of therapies specifically targeting these cells that ultimately could allow the restoration of immune tolerance within the orbit and perhaps systemically.

2007 ◽  
Vol 56 (10) ◽  
pp. 1589-1595 ◽  
Author(s):  
Stefania Scala ◽  
Caterina Ieranò ◽  
Alessandro Ottaiano ◽  
Renato Franco ◽  
Anna La Mura ◽  
...  

2017 ◽  
Vol 25 (2) ◽  
pp. 646-657 ◽  
Author(s):  
Markus Baumann ◽  
Mohammad Musarraf Hussain ◽  
Nina Henne ◽  
Daniel Moya Garrote ◽  
Stefanie Karlshøj ◽  
...  

Nanoscale ◽  
2021 ◽  
Author(s):  
Shanta Bhattarai ◽  
Yuri Mackeyev ◽  
Bhanu Venkatesulu ◽  
Sunil Krishnan ◽  
Pankaj Kumar Singh

CXC chemokine receptor 4 (CXCR4) is overexpressed on most breast cancer cell surfaces including triple negative breast cancer (TNBC) which lacks traditional receptor overexpression. We targeted gold nanoparticles (GNPs) to...


Planta Medica ◽  
2020 ◽  
Vol 86 (05) ◽  
pp. 331-337
Author(s):  
Buyun Kim ◽  
Yu-Hong Min ◽  
Byoungduck Park

AbstractMetastasis, which is closely linked to cancer-related deaths, is a highly complex process. It is an organ-specific process and involves interactions between the host and cancer cells. CXC chemokine receptor 4 is known to be expressed in various tumors and the binding with CXC ligand 12 induces signaling in cancer cell survival, migration, and proliferation. Particularly, the CXC chemokine receptor 4/CXC ligand 12 axis is known to promote the metastasis of breast cancer. Thus, agents that can downregulate CXC chemokine receptor 4 expression have potential against cancer metastasis. Minecoside is an active compound extracted from Veronica peregrina L. It is widely distributed in Korea and has been used as a traditional drug for the treatment of various chronic diseases. However, the anticancer and anti-inflammatory effects of minecoside have yet to be clarified. In this study, we found that minecoside downregulates constitutive CXC chemokine receptor 4 expression in MDA-MB-231 breast cancer cells. This downregulation also occurred at the transcriptional level. Minecoside-mediated suppression of CXC chemokine receptor 4 expression inhibited CXC ligand 12-induced invasion of breast and colorectal cancer cells. Overall, our results suggest that minecoside can be a novel anticancer agent that can inhibit cancer metastasis through inhibition of CXC chemokine receptor 4 expression.


Immunobiology ◽  
2020 ◽  
Vol 225 (2) ◽  
pp. 151902
Author(s):  
Ji Sun Paik ◽  
Sung-Eun Kim ◽  
Ji Hyun Kim ◽  
Ji-Young Lee ◽  
Suk-Woo Yang ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document